The generic name for apixaban is apixaban [1]. Apixaban is marketed as Eliquis and is a medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [2]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
How does apixaban work?
Apixaban is an anticoagulant that works by directly inhibiting Factor Xa, a key enzyme in the blood clotting cascade [3]. By blocking Factor Xa, apixaban reduces thrombin generation and thereby decreases fibrin formation, ultimately preventing blood clot formation [3].
When does patent exclusivity for Eliquis expire?
The patent exclusivity for Eliquis, the brand-name version of apixaban, is complex and involves multiple patents [4]. According to DrugPatentWatch.com, the latest patent expiry dates for apixaban-related patents are in 2030 [4].
What are the alternatives to apixaban?
Other anticoagulant medications are available, including warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), and edoxaban (Savaysa) [5]. These drugs differ in their mechanisms of action, dosing regimens, monitoring requirements, and potential side effects [5]. The choice of anticoagulant depends on individual patient factors, including the specific condition being treated, risk factors, kidney and liver function, and potential drug interactions [5].
What are the risks associated with apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [2]. This can range from minor bruising to severe, life-threatening hemorrhage [2]. Patients taking apixaban should be aware of signs of bleeding, such as unusual bruising, nosebleeds, bleeding gums, or blood in urine or stool [2]. Other potential side effects can include nausea, anemia, and allergic reactions [2].